Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GSKGLAXF -0.28%69 3-Year Book Growth Rate is 16.40% as of Jun. 2026, which is 1162% above its 10-year median of 1.30. GuruFocus rates GLAXF with a GF Score™ of 69/100 and a GF Value™ of $22.06 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 912 Drug Manufacturers companies, GSK ranks better than 82.57% on this metric.
During the past 12 months, GSK's average Book Value per Share Growth Rate was 20.50% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 16.40% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 1.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of GSK was 115.40% per year. The lowest was -52.10% per year. And the median was 1.30% per year.
GSK (OTCPK:GLAXF) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
GSK 3-Year Book Growth Rate Related Terms
GLAXF vs LLY, JNJ, ABBV: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - General subindustry, GSK's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GSK 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GSK's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where GSK's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 16.40% mean?
GSK (GLAXF) has a 3-Year Book Growth Rate of 16.40% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for GSK and its competitors. This is 1162% above median its historical median of 1.30. According to the industry distribution chart, GSK ranks #159 out of 912 companies in the Drug Manufacturers industry, placing it in the top 17.4%.
Is GSK's 3-Year Book Growth Rate too high?
GSK's current 3-Year Book Growth Rate of 16.40% is 1162% above median its 10-year median of 1.30. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.80. GSK's value of 16.40% is 241.7% above this industry median. Based on the distribution chart, GSK ranks #159 out of 912 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GSK has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's 3-Year Book Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #159 out of 912 companies for 3-Year Book Growth Rate. This places GSK in the top 17% of its industry — outperforming the majority of peers. The industry median 3-Year Book Growth Rate is 4.80. GSK's value of 16.40% is 241.7% above this benchmark. While the company's 10-year median is 1.30 vs. the industry median of 4.80, GSK has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.80, based on 912 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GSK's current 3-Year Book Growth Rate of 16.40% is 241.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for GSK and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current 3-Year Book Growth Rate is 16.40%, which is 1162% above median its own 10-year median of 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $22.06, compared to a current price of $24.95 — trading 13.1% above its estimated fair value. The current 3-Year Book Growth Rate is 16.40%, which is 1162% above median its 10-year median of 1.30 and 241.7% above the Drug Manufacturers industry median of 4.80. GSK's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For GSK (GLAXF), the current 3-Year Book Growth Rate is 16.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (GLAXF) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of $24.95 is trading 13.1% above its estimated GF Value™ of $22.06.
GuruFocus considers GSK to be Modestly Overvalued.
Key valuation signals for GLAXF:
3-Year Book Growth Rate: 16.40% (1162% above median its 10-year median of 1.30)
GF Value™: $22.06 vs. price of $24.95 (13.1% above fair value)
Industry Position: 241.7% above the Drug Manufacturers median (#159 of 912)
No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
69GF Score
Get the complete analysis for GLAXF
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLAXF has been successfully added to your 
